DMD Care UK national meeting drives improved care

DMD Care UK national meeting drives improved care

Pictured: DRF director of operations Sheli Rodney (second from right) with fellow members of the Psychosocial Working Group: disability and education specialist Dr Janet Hoskin, DMD Care UK manager Cathy Turner, Pathfinders Neuromuscular Alliance trustee Benjamin...

Solid reports positive clinical trial data

Solid Biosciences has shared positive clinical data for the first three patients in its Inspire Duchenne clinical trial. They have been dosed with Solid’s next generation gene therapy, known as SGT-003. Biopsy data at day 90 showed average microdystophin...

NICE approves DRF-funded treatment for Duchenne

New medicine for Duchenne muscular dystrophy, funded by Duchenne Research Fund and patient groups, becomes first approved treatment in the UK for all patients with Duchenne The National Institute for Health and Care Excellence (NICE) has approved vamorolone for use on...

John Walton Muscular Dystrophy Research Centre marks 10 years

We were invited to join the celebrations for the John Walton Muscular Dystrophy Research Centre’s 10th anniversary in Newcastle. The late Lord John Walton was a pioneering neurologist who made an enormous impact on muscular dystrophy diagnosis and treatment. The...

Solid expands gene therapy trial

We are pleased to share that Solid Biosciences has seen encouraging early results so far in the clinical trial of its next-generation gene therapy, SGT-003. The study, called Inspire Duchenne, began earlier this year at two sites in the US, and has already expanded to...

Solid begins dosing next-generation gene therapy

We are pleased to share that Solid Biosciences has begun dosing patients in the Phase I/II clinical study of its next-generation gene therapy, SGT-003. The study, INSPIRE DUCHENNE, is ongoing at two sites in the US – Nationwide Children’s Hospital in Columbus, Ohio,...

DMD Care UK explores next steps for patient care

On 29th February, Rare Disease Day, we were pleased to be part of the 2024 national meeting for DMD Care UK. More than 130 clinicians and 25 patient representatives are now involved in DMD Care UK, giving their time and expertise across no fewer than 13 working groups...

DMD Care UK launches new respiratory guidance

We are pleased to share that DMD Care UK’s new respiratory guidance has been endorsed by the British Thoracic Society and published in Thorax, an international peer-reviewed medical journal with a respiratory focus. It is published by the BMJ Group on behalf of...

Vamorolone approved in the UK

The Duchenne Reserach Fund is delighted to share that the MHRA (Medicines and Healthcare products Regulatory Agency) has approved vamorolone (sold under the brand name AGAMREE) for the treatment of Duchenne in patients aged 4 years and older. This is a significant...

Vamorolone approved in the EU

The European Medicines Agency (EMA) has granted marketing authorisation for vamorolone (sold under the brand name AGAMREE) for the treatment of Duchenne in patients aged 4 years and older. It is approved for all people with Duchenne, irrespective of their underlying...